Q-omics provides the consensus-scored REP15 profile across patient tissues and cancer cell-line models. REP15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, REP15 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, REP15 RNA expression shows 16,631 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, COAD, and UVM as cancer lineages where REP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REP15 survival associations across molecular data types. REP15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REP15 RNA expression–survival associations across cancer types. High REP15 expression shows unfavorable associations in LUAD, ACC, CESC, UVM and HNSC, but favorable associations in THCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for REP15 RNA expression.
This table summarizes REP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for REP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REP15 shows lower tumor expression in COAD, STAD and KICH and higher tumor expression in KIRC, KIRP and HNSC. The COAD box plot shows higher REP15 RNA expression in normal versus tumor tissue (log2 FC = −3.070, t-test p < 0.001).
This table shows molecular features associated with REP15 in patient tissues and cancer cell lines. In patient samples, REP15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, REP15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
